Drug Database
MO

molgramostim (Gramal)

✓ Approved

Probiomed · CSF2RA · 重组蛋白

什么是 molgramostim?

molgramostim 是一种重组蛋白,由Probiomed研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Gramal
公司Probiomed
药物类别重组蛋白
分子靶点CSF2RA
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

molgramostim 作用于 1 个分子靶点:

CSF2RAcolony stimulating factor 2 receptor subunit alpha (CD116, CSF2RX)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

molgramostim 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersBone marrow disorder✓ Approved

相关研究文献

PubMedSeminars in respiratory and critical care medicine2026-11-14

The Therapeutic Pipeline: Future Treatments and Precision Medicine.

Franco Giovanni G, Peri Giulia G, Ugonino-Gralino Alessia A, Galbardi Isabella I et al.

rare interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by various pathogenic mechanisms, clinical presentations, prognoses, and therapeutic challenges. Among these, acid sphingomyelinase deficiency (ASMD), pulmonary alveolar proteinosis (PAP), and pulmonary Langerhans cell histiocytosis (PLCH) exemplify rare pulmonary diseases driven by distinct biological mechanisms, including lysosomal dysfunction, impaired surfactant homeostasis, and activation of the mitogen-activated protein kinases (MAPK) pathways. Recent advancements in molecular biology, genomics, and translational research boosted the development of precision medicine strategies and disease-specific therapies for these conditions. this narrative review was conducted in accordance with the SANRA guidelines. A thorough literature search of the PubMed/MEDLINE, Embase, and Scopus databases was performed from January 2000 to June 2026. significant progress has been made in treating all three diseases. In ASMD, enzyme replacement therapy with olipudase alfa has greatly improved visceral and lung symptoms, while research in gene therapy, gene editing, and metabolic treatments is ongoing. For PAP, inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) is now the primary disease-specific treatment, now supported by phase III trial evidence for inhaled molgramostim, complemented by potential therapies such as immunomodulation, macrophage transplantation, and gene-based strategies. In PLCH, the discovery of recurrent MAPK pathway variants has supported the use of genotype-targeted treatments with BRAF and MEK inhibitors. Under these conditions, advances in molecular diagnostics, circulating biomarkers, quantitative HRCT, radiomics, and artificial intelligence (AI) are poised to enhance diagnosis, patient stratification, prognosis, and treatment decisions. ASMD, PAP and PLCH are entering into an era of precision medicine, in which disease-specific molecular mechanisms play an increasing role in guiding diagnosis and treatment. Ongoing integration of genomics, biomarkers, advanced imaging, AI, and targeted therapies could revolutionise the management of conditions such as ASMD, PAP, and PLCH, leading to better long-term patient outcomes.

PMID 43025460
阅读全文 →
PubMedRespiratory medicine and research2026-11-11

The changing landscape of autoimmune pulmonary alveolar proteinosis.

Jouneau Stéphane S, McCarthy Cormac C

Pulmonary alveolar proteinosis (PAP) should be suspected when the classic imaging finding of a "crazy paving" pattern is seen on chest CT; however, this appearance can be subtle and PAP may present with a range of varying CT features. The diagnosis is confirmed by identifying eosinophilic extracellular material that stains positively with Periodic Acid-Schiff on bronchoalveolar lavage specimens. The autoimmune form of PAP (aPAP) is confirmed by detecting anti-GM-CSF antibodies in the patient's serum. We propose a novel classification with definite, probable and possible aPAP diagnosis based on various combination of chest CT, BAL and anti-GM-CSF antibodies. Historically, whole-lung lavage has been the first-line treatment and should be performed only in expert centres. Following positive results from recent randomised, placebo-controlled trials, inhaled GM-CSF supplementation with molgramostim or sargramostim is now equally positioned as first line therapy, WLL remaining the preferred option for patients with respiratory failure, particularly at the time of diagnosis. Rituximab and plasmapheresis may be prescribed as third- and fourth-line treatments, respectively, and lung transplantation may be considered for eligible patients with end-stage respiratory failure. A deeper understanding of aPAP pathogenesis has opened new therapeutic avenues, including the use of PPARγ agonists or statins; however, future research must define the optimal long-term treatment strategy and, crucially, establish clear evidence-based criteria for when therapy should be commenced.

PMID 43014030
阅读全文 →
PubMedAnnals of the American Thoracic Society2026-09-22

Molgramostim improves exercise distance and duration in autoimmune pulmonary alveolar proteinosis: exploratory IMPALA-2 trial data.

McCarthy Cormac C, Bonella Francesco F, Inoue Yoshikazu Y, Trapnell Bruce C BC et al.

PMID 42770839
阅读全文 →
PubMedERJ open research2026-09-22

Inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) as host-directed therapy for pneumonia-related acute respiratory distress syndrome: a multicentre, randomised, placebo-controlled phase 2a trial (GI-HOPE).

Herold Susanne S, Welte Tobias T, Zacharowski Kai K, Meybohm Patrick P et al.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances pulmonary host defence and promotes re-establishment of alveolar barrier function. We investigated the safety, feasibility and efficacy of nebulised recombinant human (rh)GM-CSF (molgramostim) in pneumonia-related acute respiratory distress syndrome (ARDS). In this multicentre, randomised, double-blind, parallel-group, placebo-controlled, investigator-initiated phase 2a trial, patients were randomised to receive nebulised low-dose (150 μg) or high-dose (450 μg) rhGM-CSF or placebo for 3 days. Bronchoalveolar lavage (BAL) was performed before the first dose and after dosing. The primary outcome parameter was the composite GI-HOPE score, representing expression changes of CD80, CD86, CD206 and human leukocyte antigen (HLA)-DR on alveolar macrophages after dosing compared to baseline. Secondary outcomes included oxygenation, Sequential Organ Failure Assessment (SOFA) scores and clinical end-points at day 28. 46 participants were randomised, 43 completed treatment (n=15 placebo, n=16 low dose and n=12 high dose), and BAL was performed on 38 participants before and after treatment. Although the composite biological GI-HOPE score did not reach significance (p>0.05), high-dose treatment caused upregulation of HLA-DR and CD206 on alveolar macrophages, indicating deposition in the alveolar compartment and beneficial macrophage activation (HLA-DR: p=0.0406 versus low dose, p=0.1841 versus placebo; CD206: p=0.009 versus low dose, p=0.0179 versus placebo). High-dose rhGM-CSF treatment revealed a favourable profile of oxygenation at the end of analysis compared to time-points before inhalation (p=0.095 and p=0.0175) or compared to the low-dose and placebo groups (p=0.0063 and p=0.0198; visit 13), and was associated with decreased SOFA scores in the high-dose group over time (p=0.0013 and p=0.00023 compared to low dose and placebo). Importantly, inhaled rhGM-CSF did not increase alveolar or systemic inflammation. Inhalation of 450 μg rhGM-CSF was safe, and promoted a favourable profile regarding alveolar macrophage activation, oxygenation and SOFA scores over time; however, it did not lead to differences in the GI-HOPE score.

PMID 42769414
阅读全文 →
PubMedBMC pulmonary medicine2026-02-26

Efficacy of recombinant human GM-CSF compared to placebo for autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis.

Naeem Umaimah U, Zahid Hafiza Fatima HF, Imtiaz Sarah S, Khan Quratulain Q et al.

BACKGROUND: Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare interstitial lung disease characterized by surfactant accumulation within alveoli due to impaired clearance or GM-CSF signaling defect. Whole lung lavage (WLL) removes accumulated surfactant but is invasive and does not correct macrophages dysfunction. Recombinant GM-CSF (molgramostim or sargramostim) aims to restore macrophage activity¸ enhance gas exchange and reduce dependence on WLL. OBJECTIVE: This systematic review and meta-analysis evaluated the efficacy of recombinant human GM-CSF (molgramostim or sargramostim) compared with placebo in patients with aPAP. METHOD: Following PRISMA guidelines, PubMed, Cochrane CENTRAL, and Scopus were searched for randomized controlled trials in adults with aPAP receiving molgramostim or sargramostim versus placebo. Primary outcomes included changes in alveolar–arterial oxygen gradient (A-aDO₂) and diffusing capacity of the lung for carbon monoxide (DLCO). Secondary outcomes included St. George’s Respiratory Questionnaire (SGRQ) scores, radiologic ground-glass opacity (GGO) scores, vital capacity, six-minute walk distance, serum biomarkers (CEA and KL-6), and GM-CSF autoantibody levels. Data were analyzed using a random-effects model RevMan 5.4.1, and risk of bias with ROB 2.0. RESULT: Four RCTs involving 338 participants (190 interventions,148 control) were included. Recombinant GM-CSF significantly improved gas exchange, with decreased A-aDO₂ MD of -4.67 (95% CI: -8.49 to -1.42, p = 0.006) and increased DLCO (% predicted) with a mean difference of 6.13 (95% CI: 3.36 to 8.89). Significant improvements were also observed in SGRQ-T scores (MD = –6.60; p < 0.00001) and GGO scores (MD = –1.98; p = 0.0007). No significant differences were found for six-minute walk distance, vital capacity, or serum biomarkers. Most included trials showed low to moderate risk of bias with a few high risk. Egger’s test (p = 0.37) showed no publication bias and overall certainty of evidence ranged from moderate to high. CONCLUSION: Recombinant GM-CSF (molgramostim and sargramostim) is an effective, disease targeted therapy for aPAP. It improves pulmonary function gas exchange and radiological outcomes while reducing reliance on whole lung lavage. TRIAL REGISTRATION: PROSPERO reference number CRD420251165258.

PMID 41742124
阅读全文 →
PubMedImmunotherapy2025-10-14

Recombinant GM-CSF drug evaluation review.

McCarthy Jack J, Boyle Niamh N, McCarthy Cormac C

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare disease characterized by myeloid cell dysfunction, abnormal pulmonary surfactant accumulation, and innate immune deficiency. Pathogenesis is driven by GM-CSF neutralizing autoantibodies (GMAbs) present in high titer in serum and bronchoalveolar lavage fluid (BALF) of patients. GM-CSF is a cytokine and a hematopoietic growth factor produced by a variety of cells. In the lungs, GM-CSF regulates surfactant homeostasis and lung host defense through innate immune function. Whole lung lavage (WLL) is the current first line therapy for aPAP. It is a procedure in which excessive surfactant is mechanically removed from the alveoli. Pathogenesis-driven treatment with GM-CSF augmentation has been investigated over the last two decades with recombinant GM-CSF (rGM-CSF). Molgramostim and sargramostim are rGM-CSF which can be self-administered at home by patients with aPAP either subcutaneously or using a handheld nebulizer. In Phase II and III studies of adults with aPAP, daily administration of inhaled molgramostim resulted in greater improvements in pulmonary gas transfer and functional health status than placebo, with similar rates of adverse events. In all clinical studies to date, rGM-CSF has shown a favorable safety profile with no dose limiting toxicity. This supports the application of inhaled rGM-CSF for the treatment of aPAP and the possibility of WLL as a rescue therapy.

PMID 41085041
阅读全文 →

注册免费账户还可查看另外 67 篇文献

免费注册查看全部文献 →

了解更多molgramostim